Table 3.
Assessment of the Elecsys® Zika IgG assay in potentially cross-reacting samples.
| Pathogen | N | Non-Reactive | Reactive |
|---|---|---|---|
| DENV | 30 | 30 | 0 |
| Cytomegalovirus | 12 | 12 | 0 |
| Epstein–Barr virus | 11 | 11 | 0 |
| Herpes simplex virus | 10 | 10 | 0 |
| Hepatitis A virus | 8 | 8 | 0 |
| Rubella virus | 12 | 12 | 0 |
| Hepatitis B virus | 11 | 11 | 0 |
| Hepatitis C virus | 12 | 12 | 0 |
| Plasmodium falciparum/vivax (malaria) | 11 | 11 | 0 |
| Treponema pallidium (syphilis) | 12 | 12 | 0 |
| Varicella zoster virus | 12 | 12 | 0 |
| TBE virus | 20 | 20 | 0 |
| Yellow fever virus | 15 | 15 | 0 |
| Japanese encephalitis virus | 3 | 3 | 0 |
| Antinuclear antibodies | 12 | 12 | 0 |
| Rheumatoid factor | 11 | 11 | 0 |